@article{fdi:010085353,
  title = {{C}apacity building in {S}ub-{S}aharan {A}frica as part of the {INTENSE}-{TBM} project during the {COVID}-19 pandemic [{C}ommentaire]},
  author = {{A}riza-{V}ioque, {E}. and {E}llo, {F}. and {A}ndriamamonjisoa, {H}. and {M}achault, {V}. and {G}onzalez-{M}artin, {J}. and {C}alvo-{C}ortes, {M}. {C}. and {E}holie, {S}. and {T}chabert, {G}. {A}. and {O}uassa, {T}. and {R}aberahona, {M}. and {R}akotoarivelo, {R}. and {R}azafindrakoto, {H}. and {R}ahajamanana, {L}. and {W}ilkinson, {R}. {J}. and {D}avis, {A}. and {M}axebengula, {M}. and {A}brahams, {F}. and {M}uzoora, {C}. and {N}akigozi, {N}. and {N}yehangane, {D}. and {N}anjebe, {D}. and {M}bega, {H}. and {K}aitano, {R}. and {B}onnet, {M}aryline and {B}eaudrap, {P}ierre de and {M}iro, {J}. {M}. and {A}nglaret, {X}. and {R}akotosamimanana, {N}. and {C}almy, {A}. and {B}onnet, {F}. and {A}mbrosioni, {J}. and {INTENSE}-{TBM} {G}roup},
  editor = {},
  language = {{ENG}},
  abstract = {{T}uberculous meningitis ({TBM}) is the most severe and disabling form of tuberculosis ({TB}), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 ({HIV}-1). {T}o evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the {INTENSE}-{TBM} project includes a phase {III} randomised clinical trial ({TBM}-{RCT}) in four countries in sub-{S}aharan {A}frica ({SSA}). {W}ithin this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the {TBM}-{RCT} and developing a network of skilled researchers, clinical centres and microbiology laboratories. {H}ere, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 ({COVID}-19) pandemic. {D}espite major challenges, {TBM}-{RCT} initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in {SSA}. {I}n terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. {P}latform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in {A}frica.},
  keywords = {{A}frica ; {C}apacity building ; {C}linical research ; {HIV} ; {INTENSE}-{TBM} ; {T}uberculous meningitis ; {AFRIQUE} {SUBSAHARIENNE} ; {COTE} {D}'{IVOIRE} ; {MADAGASCAR} ; {AFRIQUE} {DU} {SUD} ; {OUGANDA}},
  booktitle = {},
  journal = {{I}nfectious {D}iseases and {T}herapy},
  volume = {11},
  numero = {4},
  pages = {1327--1341},
  ISSN = {2193-8229},
  year = {2022},
  DOI = {10.1007/s40121-022-00667-z},
  URL = {https://www.documentation.ird.fr/hor/fdi:010085353},
}